Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 20/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20568231 | 1.00 | PDE5A (0.75) | PDE5A | |
| SCHEMBL30575418 | 0.94 | PDE5A (0.76) | PDE5A | |
| SCHEMBL20568047 | 0.94 | PDE5A (0.76) | PDE5A | |
| SCHEMBL31268477 | 0.91 | PDE5A (0.82) | PDE5A | |
| SCHEMBL20568045 | 0.90 | PDE5A (0.82) | PDE5A | |
| SCHEMBL31651386 | 0.90 | PDE5A (0.82) | PDE5A | |
| SCHEMBL31268448 | 0.90 | PDE5A (0.84) | PDE5A | |
| SCHEMBL20569037 | 0.89 | PDE5A (0.82) | PDE5A | |
| SCHEMBL30575409 | 0.89 | PDE5A (0.82) | PDE5A | |
| SCHEMBL22065426 | 0.88 | PDE5A (0.88) | PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3630769-B1 | NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | TOPADUR PHARMA AG (CH) | 2025-07-02 | — | — | EP | claimed |
| EP-4486349-A1 | TOPICAL COMPOSITIONS AND USES THEROF | Topadur Pharma AG (CH) | 2025-01-08 | — | — | EP | claimed |
| CN-118891047-A | Topical composition and use thereof | 托帕杜制药公司 | 2024-11-01 | — | — | CN | claimed |
| CN-118063458-A | Novel dual mode of action of soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof | 托帕杜制药公司 | 2024-05-24 | — | — | CN | claimed |
| WO-2023166013-A9 | TOPICAL COMPOSITIONS AND USES THEROF | TOPADUR PHARMA AG (CH) | 2024-05-23 | — | — | WO | claimed |
| CN-110621676-B | Dual mode of action of soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof | 托帕杜制药公司 | 2024-02-09 | — | — | CN | claimed |
| WO-2023166013-A1 | TOPICAL COMPOSITIONS AND USES THEROF | TOPADUR PHARMA AG (CH) | 2023-09-07 | — | — | WO | claimed |
| WO-2023167503-A1 | TRANSDERMAL DOSAGE FORM, FOR PROMOTING LOCAL BLOOD FLOW, OF DUAL-ACTING PDE5 INHIBITOR/ORGANIC NITRATE ESTER | 연세대학교 산학협력단 | 2023-09-07 | — | — | WO | claimed |
| EP-4486349-A1 | TOPICAL COMPOSITIONS AND USES THEROF | Topadur Pharma AG (CH) | 2025-01-08 | — | — | EP | disclosed |
| CN-118891047-A | Topical composition and use thereof | 托帕杜制药公司 | 2024-11-01 | — | — | CN | disclosed |
| CN-118063458-A | Novel dual mode of action of soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof | 托帕杜制药公司 | 2024-05-24 | — | — | CN | disclosed |
| WO-2023166013-A9 | TOPICAL COMPOSITIONS AND USES THEROF | TOPADUR PHARMA AG (CH) | 2024-05-23 | — | — | WO | disclosed |
| CN-110621676-B | Dual mode of action of soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof | 托帕杜制药公司 | 2024-02-09 | — | — | CN | disclosed |
| WO-2023166013-A1 | TOPICAL COMPOSITIONS AND USES THEROF | TOPADUR PHARMA AG (CH) | 2023-09-07 | — | — | WO | disclosed |
| WO-2023167503-A1 | TRANSDERMAL DOSAGE FORM, FOR PROMOTING LOCAL BLOOD FLOW, OF DUAL-ACTING PDE5 INHIBITOR/ORGANIC NITRATE ESTER | 연세대학교 산학협력단 | 2023-09-07 | — | — | WO | disclosed |